RESUMEN
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support.
Asunto(s)
Anemia , Neoplasias de la Mama , Inmunoconjugados , Trombocitopenia , Humanos , Femenino , Ado-Trastuzumab Emtansina/uso terapéutico , Receptores de Trombopoyetina/uso terapéutico , Receptor ErbB-2/genética , Receptor ErbB-2/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Trastuzumab/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/patología , Trombocitopenia/inducido químicamente , Trombocitopenia/tratamiento farmacológico , Anemia/inducido químicamente , Inmunoconjugados/uso terapéuticoRESUMEN
Atypical chronic lymphocytic lymphoma (CLL) with CCND1 translocation is poorly described, particularly in the era of modern inhibitors of the B-cell receptor pathway. We present a patient with atypical CLL who had a significant response to ibrutinib, highlighting the effectiveness of this agent in higher risk CLL subgroups.